GlassScriptPhysician profile
William David Hoover
NPI 1720064116
$594,145.86
in general payments reported to CMS, 2019-2025
27 companies · $98K in 2025
The $98K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $19K · 2021: $24K · 2022: $124K · 2023: $119K · 2024: $126K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Travel and Lodging: $42K · Consulting Fee: $27K · Food and Beverage: $12K · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262,729.17 |
| Travel and Lodging | $41,539.01 |
| Consulting Fee | $26,745.00 |
| Food and Beverage | $12,157.88 |
| Education | $159.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501,853.93 | 2019-2025 | |
| Lilly USA, LLC | $82,676.57 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $3,075.70 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $2,798.73 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $536.85 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $470.13 | 2024-2025 | |
| Leo Pharma INC. | $445.11 | 2022-2025 | Adbry |
| Ucb, INC. | $403.53 | 2024-2025 | Bimzelx |
| Pfizer INC. | $225.32 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $225.16 | 2019-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $206.94 | 2019-2024 | Cabtreo, Jublia |
| Genzyme Corporation | $197.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $154.44 | 2019-2025 | |
| Amgen INC. | $119.59 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $116.86 | 2024-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $111.19 | 2019-2025 | Seysara |
| Medimetriks Pharmaceuticals, INC. | $104.95 | 2025 | Clindacin Etz, Neuac |
| Journey Medical Corporation | $92.07 | 2019-2025 | |
| Dermavant Sciences, INC. | $83.28 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $68.78 | 2024-2025 | Nemluvio |
| Organon LLC | $54.02 | 2024 | |
| Cipher Pharmaceuticals US LLC | $30.44 | 2025 | Natroba, Spinosad |
| Botanix Sb INC | $24.22 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.76 | 2025 | Spevigo |
| Incyte Corporation | $19.83 | 2021 | |
| Hikma Pharmaceuticals USA | $15.13 | 2020 | |
| Allergan, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.